Popular Trials
Virus Therapy
HLA-matched VSTs for Viral Infections Post Stem Cell Transplant
This trial is for patients who have had a stem cell transplant and have developed a viral infection that is not responding to standard therapy. In this trial, the patient will receive white blood cells that have been specially trained to fight the viral infection.
Popular Filters
Trials for Cytomegalovirus Infection Patients
Virus Therapy
Virus-Specific T-Cell Therapy for Infections
This trial tests special immune cells designed to fight specific viruses in patients with weak immune systems or those who have had transplants. These patients have infections that don't respond to regular treatments. The donor immune cells help attack the viruses in their bodies. This approach has shown promise in enhancing immune responses to viruses like CMV and EBV.
Trials for Chronic Lymphocytic Leukemia Patients
Virus Therapy
CMV-Specific T-Cells for Cytomegalovirus Infection
This trial looks at whether white blood cells from donors who have been exposed to cytomegalovirus can help treat patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
Virus Therapy
Letermovir for Preventing Infection in Blood Cancer Patients
This trial studies how well letermovir prevents CMV reactivation in patients with blood cancers treated with alemtuzumab. Letermovir works by stopping the virus from making more copies of itself. The goal is to see if it can effectively prevent CMV infections in these patients. Letermovir is an antiviral drug approved for preventing CMV infections, primarily studied for a few months after treatment.
Trials With No Placebo
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
View More Related Trials
Frequently Asked Questions
Introduction to cmv
What are the top hospitals conducting cmv research?
When it comes to the cutting-edge research and treatment of cytomegalovirus (CMV), leading hospitals across the United States are paving the way for advancements in this field. Located in Duarte, California, City of Hope Medical Center is at the forefront with eight ongoing CMV trials. This medical center is dedicated to finding innovative solutions for CMV, a common virus that can cause complications in immunocompromised individuals. While their all-time record may show zero completed trials, their commitment to pushing boundaries in CMV research is evident.
Meanwhile, Crossroads Clinical Research located in Victoria also joins the league by actively conducting three clinical trials focused on CMV. Despite not having any past completed studies listed, this hospital's dedication to investigating potential treatments and therapies for CMV demonstrates its commitment to improving patient outcomes.
In Boston, Dana-Farber Cancer Institute is making strides with three active clinical trials dedicated solely to combating CMV. As one of the premier cancer institutes worldwide, Dana-Farber recognizes that CMV can pose significant challenges for patients undergoing cancer treatment or those who have received organ transplants.
Nationwide Children's Hospital situated in Columbus shares a similar focus on understanding and treating CMV infections among young patients. With three ongoing clinical trials centered around this condition, they provide hope for children affected by this potentially harmful virus.
Lastly but certainly not least important; The esteemed Children's Hospital of Philadelphia located right within Philadelphia itself also contributes significantly towards tackling Cytomegalovirus (CM) through its own cluster containing a total count of active-three investigations.Furthermore no recorded investigation has been concluded yet however considering these efforts being made it surely paints an optimistic picture regarding future prospects
Through these collaborative efforts from top-tier hospitals across different states in America , there lies great potential toward developing improved strategies against cmv -strategies which will ultimately benefit countless individuals facing such health concerns nationwide
Which are the best cities for cmv clinical trials?
When it comes to CMV clinical trials, several cities are leading the way in research and development. Houston, Texas, stands out with 15 active trials investigating treatments like mRNA-1647 Dose A, HLA-matched VSTs, and Vaccine Group. Columbus, Ohio follows closely behind with 12 ongoing studies focused on Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes and other potential interventions. New york City also proves to be a hub for CMV research with 10 active trials exploring treatments such as Valganciclovir and Lung Transplant Recipients. Boston, Massachusetts offers another promising location for CMV clinical trials with 8 ongoing studies examining treatment options like PEP-CMV and Vaccine Group. Lastly, Duarte, California contributes to the advancement of CMV research through its participation in 8 active trials exploring innovative approaches including tetanus-CMV fusion peptide vaccine and Multipeptide CMV-Modified Vaccinia Ankara Vaccine. These cities provide individuals affected by CMV access to cutting-edge clinical trials that pave the way for improved care outcomes.
Which are the top treatments for cmv being explored in clinical trials?
In the realm of clinical trials for CMV treatment, a few notable contenders have emerged. One standout is Letermovir, which has been the subject of 29 all-time trials and is currently being explored in six active studies. Another promising option is Maribavir, with four ongoing trials and a total of 26 past investigations dedicated to its potential effectiveness against CMV. These treatments hold great promise in advancing our understanding and management of this complex viral infection.
What are the most recent clinical trials for cmv?
Exciting advancements are being made in the field of CMV treatment through recent clinical trials. One promising trial involves the use of innovative treatments such as CMV-specific CD19-CAR T cells and a triplex vaccine. This Phase 1 study, which became available on 9/13/2023, aims to explore their effectiveness for combating CMV infection. Another Phase 2 trial focuses on lung transplant recipients who are particularly vulnerable to CMV complications. This study, available from 9/1/2023, seeks to identify optimal treatment approaches specific to this patient population. Additionally, another Phase 2 trial called Cohort A is investigating potential therapeutic options for CMV infections. These studies offer hope for improved management and outcomes in individuals affected by CMV.
What cmv clinical trials were recently completed?
Three recent clinical trials have investigated potential treatments for cytomegalovirus (CMV). In September 2021, a trial sponsored by the National Institute of Allergy and Infectious Diseases evaluated the efficacy of an experimental CMV vaccine. Another trial conducted by Duke University Medical Center focused on testing a novel antiviral therapy against CMV in June 2021. Additionally, in January 2021, a trial led by the University of Alabama at Birmingham explored the use of adoptive T-cell therapy to target CMV infection. These studies signify important strides towards advancing our understanding and treatment options for this challenging viral infection.